Rafael Molina
- Oncology top 2%
- Molecular Biology
- Radiology, Nuclear Medicine and Imaging top 5%
- Cancer Research top 5%
- Pulmonary and Respiratory Medicine top 10%
- Co-authors
- Kennedy W. GilchristGary M. ClarkXavier FilellaAntonio M. BallestaC. Kent OsborneD. Craig AllredMartin D. AbeloffAmol Tandon
- Topics
- Peptidase Inhibition and Analysis (9 papers)HER2/EGFR in Cancer Research (9 papers)Lung Cancer Research Studies (6 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaNature Biotechnology
- Partner nations
- SpainUnited StatesNetherlands
In The Last Decade
Rafael Molina
32 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 90
- Oncology 1.1k
- Molecular Biology 557
- Radiology, Nuclear Medicine and Imaging 476
- Cancer Research 473
- Pulmonary and Respiratory Medicine 222
Countries citing papers authored by Rafael Molina
This map shows the geographic impact of Rafael Molina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael Molina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael Molina more than expected).
Fields of papers citing papers by Rafael Molina
This network shows the impact of papers produced by Rafael Molina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael Molina. The network helps show where Rafael Molina may publish in the future.
Co-authorship network of co-authors of Rafael Molina
This figure shows the co-authorship network connecting the top 25 collaborators of Rafael Molina. A scholar is included among the top collaborators of Rafael Molina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael Molina. Rafael Molina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 11 | |
| 4 | 31 | |
| 5 | 175 | |
| 6 | 6 | |
| 7 | Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. | 41 |
| 8 | 26 | |
| 9 | C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. | 74 |
| 10 | 50 | |
| 11 | 57 | |
| 12 | 22 | |
| 13 | 62 | |
| 14 | 89 | |
| 15 | 60 | |
| 16 | 329 | |
| 17 | 385 | |
| 18 | Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9. | 3 |
| 19 | 11 | |
| 20 | 8 |
About Rafael Molina
Rafael Molina is a scholar working on Oncology, Cancer Research and Biotechnology, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (9 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Research Studies (6 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (473 citations) and Radiology, Nuclear Medicine and Imaging (476 citations). Rafael Molina has collaborated with scholars based in Spain, United States and Netherlands. Frequent co-authors include Kennedy W. Gilchrist, Gary M. Clark, Xavier Filella, Antonio M. Ballesta, C. Kent Osborne, D. Craig Allred, Martin D. Abeloff, Amol Tandon, Edward G. Mansour and D C Tormey. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.